Elixir Associates

Myricx Bio have successfully raised a £90/$114 Million in Series A funding. 👏 💷 🔎 The company's technology is based on research from Imperial College London & The Francis Crick Institute and has secured Series A funding from Novo Holdings, Abingworth, British Patient Capital, Cancer Research Horizons, Eli Lilly and Company, Brandon Capital and Sofinnova Partners. ➖ Robin Carr - (Chief Executive Officer) ➖ Francesca Zammarchi - (Chief Scientific Officer) ➖ Julie Mead - (Chief Financial Officer/ Chief Operating Officer) ➖ Robert McLeod - (Vice President, Clinical Development) Huge congratulations to the whole Myricx Bio family from everyone at Elixir Associates. 🔵🟡 #Elixir #Congratulations #Biotech #LifeSciences #News #Funding #SeriesA #Pharma #Financing #ADC #Oncology #Cancer

Big moves in the fight against prostate cancer! Merck has just landed exclusive global rights to opevesostat, a potential game-changer for metastatic castration-resistant prostate cancer. Fresh off their collaboration with Orion Corporation, Merck is now steering the wheel solo in the Phase 3 trials 📊✅ Orion's handover is strategic, allowing them to channel their energies into other projects while staying on board the opevesostat journey through milestones and royalties. It's about smarter resource allocation and trust in Merck's ability to push the boundaries further 🚀 With Orion's eyes on a large sum of milestones reaching up to $625 million, not to mention the potential $975 million in sales milestones, transparent partnerships like these show us the value of joining forces in the Life Sciences 🤝 #Merck #OrionCorporation #LiisaHurme #Oncology #ProstateCancer #LifeScience #ClinicalResearch #ClinicalTrials #Biotechnology #Pharmaceuticals #ElixirAssociates

Exciting news from the frontlines of cancer treatment: Epsilogen has just secured the green light from the UK's MHRA to proceed with a groundbreaking Phase Ib study of MOv18 IgE, targeting platinum-resistant ovarian cancer (PROC). The implications of this are immense. For those enduring PROC, treatment options are often limited, making the prospect of a novel therapy highly encouraging. MOv18 IgE is an IgE antibody targeting the folate receptor alpha, a common antigen in certain cancers. This development isn't limited to ovarian cancer; it paves the way for future breakthroughs in treating a range of malignancies. This trial will rigorously assess MOv18 IgE's safety, tolerability, and efficacy—crucial steps toward potentially revolutionizing the treatment of PROC. With an anti-tumor impact already observed in initial trials, the outlook is promising. #CancerResearch #ClinicalTrials #LifeSciences

Get to know the Elixir Associates Family 🔵🟡 Under the Spotlight today is Jake Couldrick -✨ Outside of work, Jake loves spending time with his family, going to watch his beloved Chelsea and Social Food & Drinks (more drinks than food🍻) ➖ Favourite Animal: Dog ➖ Favourite Holiday Destination: Ibiza ➖ Countries on your bucket list: Japan or Tanzania ➖ Favourite Cuisine: Japanese or Italian, but for my last meal I’m eating a pie and its not even close 🥧 ➖Favourite Movie: Django Unchained or The Dark Knight🎥 ➖ Favourite Music Genre: HipHop & Classical🎶 ➖ Favourite Actor: Leonardo Di Caprio or Robin Williams 🎞 ➖ Favourite Actress: Catherine Tate ➖ Favourite Comedian: Dave Chapelle or Ricky Gervais ➖ Favourite Fruit: Mango 🥭 ➖ Favourite Quote: “Yesterday is history, tomorrow is a mystery but today is a gift that is why we call it the present” Eleanor Roosevelt or Mater Oogway for those in the know! 🐢 ➖ Favourite Colour: British Racing Green ➖ Favourite Sports Team: Chelsea   ➖ Favourite Dessert: Sticky Toffee Pudding, Apple Crumble I’m sorry! ➖ Currently Reading: I am ashamed to say the honest answer is nothing, I bought Supercommunitcators two months ago and haven’t made the time to start 😞 #Elixir #FunFacts #GetToKnow #Staffing #Leaders #Recruitment #Biotech #Hiring #Pharma

Get to know the Elixir Associates Family 🔵🟡 Under the Spotlight today is Jake Couldrick -✨ Outside of work, Jake loves spending time with his family, going to watch his beloved Chelsea and Social Food & Drinks (more drinks than food🍻) ➖ Favourite Animal: Dog ➖ Favourite Holiday Destination: Ibiza ➖ Countries on your bucket list: Japan or Tanzania ➖ Favourite Cuisine: Japanese or Italian, but for my last meal I’m eating a pie and its not even close 🥧 ➖Favourite Movie: Django Unchained or The Dark Knight🎥 ➖ Favourite Music Genre: HipHop & Classical🎶 ➖ Favourite Actor: Leonardo Di Caprio or Robin Williams 🎞 ➖ Favourite Actress: Catherine Tate ➖ Favourite Comedian: Dave Chapelle or Ricky Gervais ➖ Favourite Fruit: Mango 🥭 ➖ Favourite Quote: “Yesterday is history, tomorrow is a mystery but today is a gift that is why we call it the present” Eleanor Roosevelt or Mater Oogway for those in the know! 🐢 ➖ Favourite Colour: British Racing Green ➖ Favourite Sports Team: Chelsea   ➖ Favourite Dessert: Sticky Toffee Pudding, Apple Crumble I’m sorry! ➖ Currently Reading: I am ashamed to say the honest answer is nothing, I bought Supercommunitcators two months ago and haven’t made the time to start 😞 #Elixir #FunFacts #GetToKnow #Staffing #Leaders #Recruitment #Biotech #Hiring #Pharma

Happy Independence Day to all those celebrating across the United States from all of us here at Elixir Associates !!! 🎆 Wishing you all a day filled with BBQs, Fireworks & Quality Time with your loved ones. (Today is also an excuse to watch one of the best films ever made from 1996) - 📽🍿 #Elixir #IndependenceDay #July4th #Celebration

🚀 !Incredible Clinical Trial for Frontotemporal Dementia Begins in the U.S.! 🚀 AviadoBio's ASPIRE-FTD Phase 1/2 Clinical Trial is now open at The Ohio State University Wexner Medical Center! ASPIRE-FTD recruits participants to evaluate AVB-101, a gene therapy designed to stop FTD progression caused by GRN mutations. The study is also ongoing in Europe, and aims to restore progranulin levels! The therapy is delivered to the thalamus via a minimally invasive procedure. Why This Matters: 🧠 FTD impacts those under 65, causing personality changes, behavioral issues, and loss of language and mobility. With no current treatments, this trial offers a new course of therapy. 🧠"People with FTD-GRN have no disease-modifying treatments, and the impact is profound for patients and families," said Dr. James Elder, neurosurgeon at The Ohio State University Wexner Medical Center #GeneTherapy #FTD #NeurodegenerativeDisorders #ClinicalTrials #MedicalResearch #Neurology #Neurosurgery #OhioState #AviadoBio #InnovationInMedicine #GRNMutations #AVB101 #EarlyOnsetDementia #MedicalBreakthroughs Image: Fig. 1a | Intrathalamic gene therapy delivery in sheep. MRI image of sheep skull demonstrating simulated bilateral intrathalamic infusion (blue) into the brain. https://lnkd.in/ebgB5Vz3

🔬 EHA 2024 delivered yet another year of groundbreaking research, and one standout theme was clear—monoclonal antibodies are still leading the charge in multiple myeloma treatment. Following impressive findings from research like the DREAMM-8 trial, it's undeniable that treatments like Blenrep are transforming patient outcomes. With a remarkable median PFS yet to be reached and a notable increase in overall survival rates, these advancements highlight how far we've come in combating this persistent blood cancer. Witnessing the potential of newer players such as linvoseltamab and Sarclisa, we're reminded of the rapid pace at which the field of hematological malignancies evolves. These therapies are not just about prolonging life, but also about improving the quality of those extended years. To those looking to make your next strategic career move in this promising field—let's talk. For companies scaling up to meet the challenges and opportunities presented by these innovations, remember that the right talent can propel your treatments from trial to triumph. At Elixir Associates, we're poised to partner with you to secure game-changers for your teams. For fresh insights or if you're ready to seize new opportunities, don't hesitate to contact us.. 🔗 Let's keep the conversation going - share your thoughts on the future of multiple myeloma treatments below or drop me a line! #MultipleMyeloma #ClinicalTrials #LifeSciences

Great news in the world of medicine - the FDA has approved selpercatinib for use in pediatric patients battling thyroid cancer. As of June 12, selpercatinib extends a lifeline to adults and children older than 2 years with certain advanced thyroid cancers. This milestone represents more than just another treatment option; clinical evidence is compelling, with a significant portion of patients showing favorable responses. While we should be mindful of the side effects, the potential benefits for individuals with RET fusion-positive thyroid cancer are too substantial to overlook. #HealthcareAdvancement #FDAApproval #MedicalInnovation

Beacon Therapeutics have successfully raised a $170 Million in Series B funding, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials. 👏👁 🔎 The funding round was led by Forbion, TCGX & Advent Life Sciences, with initial investments from Syncona Limited & Oxford Science Enterprises. ➖ David Fellows - (Chief Executive Officer) ➖ Abraham Scaria - (Chief Scientific Officer) ➖ Andrew Prosser FCA - (Chief Financial Officer) ➖ Nadia Waheed - (Chief Medical Adviser) Huge congratulations to the whole Beacon family from everyone at Elixir Associates. 🔵🟡 #Elixir #Congratulations #Biotech #LifeSciences #News #Funding #SeriesB #Pharma #Financing #Therapeutics #Ophthalmology